Potential Therapeutic Targets and Research Progress of Related Drugs of Heart Failure

Mei YANG; Ping WANG; Hui YANG; Gonghao HE

doi:10.12259/j.issn.2095-610X.S20230719

Volume 44 Issue 7

Jul. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2023 > 44(7): 156-161

Mei YANG, Ping WANG, Hui YANG, Gonghao HE. Potential Therapeutic Targets and Research Progress of Related Drugs of Heart Failure[J]. Journal of Kunming Medical University, 2023, 44(7): 156-161. doi: 10.12259/j.issn.2095-610X.S20230719

Citation:

Mei YANG, Ping WANG, Hui YANG, Gonghao HE. Potential Therapeutic Targets and Research Progress of Related Drugs of Heart Failure[J]. Journal of Kunming Medical University, 2023, 44(7): 156-161. doi: 10.12259/j.issn.2095-610X.S20230719

Citation:

PDF( 605 KB)

Potential Therapeutic Targets and Research Progress of Related Drugs of Heart Failure

doi: 10.12259/j.issn.2095-610X.S20230719

1.
Dept. of Clinical Pharmacy，920th Hospital of Joint Logistics Support Force of People’s Liberation Army，Kunming Yunan 650032
2.
Biomedical Engineering Research Center，Kunming Medical University，Kunming Yunnan 650500，China

Received Date: 2022-03-01
Available Online: 2023-07-18
Publish Date: 2023-07-25

Abstract

Abstract

Heart failure is one of the main causes of death in cardiovascular diseases. With the increasing prevalence of heart failure, it has become the main research direction to explore new therapeutic targets and further reduce the mortality of patients. This review provided a comprehensive overview of the different targets for heart failure therapy, including the G protein-coupled receptor family, Na⁺/H⁺ exchangers, deacetylase family, inflammatory cytokines and chemokines etc., by searching and collating studies related to heart failure therapeutic targets published in China and abroad. It provided new ideas for the treatment of heart failure and the development of new drugs.
- Heart failure,
- Target,
- Drug

FullText(HTML)

References(50)

References

[1]	Ghionzoli N,Gentile F,Del Franco A M,et al. Current and emerging drug targets in heart failure treatment[J]. Heart Fail Rev,2022,27(4):1119-1136. doi: 10.1007/s10741-021-10137-2
[2]	Castiglione V,Aimo A,Vergaro G,et al. Biomarkers for the diagnosis and management of heart failure[J]. Heart Fail Rev,2022,27(2):625-643. doi: 10.1007/s10741-021-10105-w
[3]	Bhatt K N,Butler J. Myocardial energetics and heart failure: A review of recent therapeutic trials[J]. Curr Heart Fail Rep,2018,15(3):191-197. doi: 10.1007/s11897-018-0386-8
[4]	Chen Y,He Q,Mo D C,et al. The angiotensin receptor and neprilysin inhibitor,LCZ696,in heart failure: A meta-analysis of randomized controlled trials[J]. Medicine (Baltimore),2022,101(41):e30904.
[5]	Hilger D,Masureel M,Kobilka B K. Structure and dynamics of GPCR signaling complexes[J]. Nat Struct Mol Biol,2018,25(1):4-12. doi: 10.1038/s41594-017-0011-7
[6]	Wang J,Gareri C,Rockman H A. G-protein-coupled receptors in heart disease[J]. Circ Res,2018,123(6):716-735. doi: 10.1161/CIRCRESAHA.118.311403
[7]	Rueda P,Merlin J,Chimenti S,et al. Pharmacological insights into safety and efficacy determinants for the development of adenosine receptor biased agonists in the treatment of heart failure[J]. Front Pharmacol,2021,12:628060. doi: 10.3389/fphar.2021.628060
[8]	Meibom D,Albrecht-Küpper B,Diedrichs N,et al. Neladenoson bialanate hydrochloride: A prodrug of a partial adenosineA1 receptor agonist for the chronic treatment of heart diseases[J]. Chem Med Chem,2017,12(10):728-737. doi: 10.1002/cmdc.201700151
[9]	Voors A A,Bax J J,Hernandez A F,et al. Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: A phase IIb,randomized,double-blind,placebo-controlled trial[J]. Eur J Heart Fail,2019,21(11):1426-1433. doi: 10.1002/ejhf.1591
[10]	Neumann J,Kirchhefer U,Dhein S,et al. The roles of cardiovascular H2-histamine receptors under normal and pathophysiological conditions[J]. Front Pharmacol,2021,12:732842. doi: 10.3389/fphar.2021.732842
[11]	Saheera S,Potnuri A G,Guha A,et al. Histamine 2 receptors in cardiovascular biology: A friend for the heart[J]. Drug Discov Today,2022,27(1):234-245. doi: 10.1016/j.drudis.2021.08.008
[12]	Luo T,Chen B,Zhao Z,et al. Histamine H2 receptor activation exacerbates myocardial ischemia/reperfusion injury by disturbing mitochondrial and endothelial function[J]. Basic Res Cardiol,2013,108(3):342. doi: 10.1007/s00395-013-0342-4
[13]	Zeng Z,Shen L,Li X,et al. Disruption of histamine H2 receptor slows heart failure progression through reducing myocardial apoptosis and fibrosis[J]. Clin Sci (Lond),2014,127(7):435-48. doi: 10.1042/CS20130716
[14]	Gergs U,Kirchhefer U,Bergmann F,et al. Characterization of stressed transgenic mice overexpressing H2-histamine receptors in the heart[J]. J Pharmacol Exp Ther,2020,374(3):479-488. doi: 10.1124/jpet.120.000063
[15]	Gergs U,Büxel M L,Bresinsky M,et al. Cardiac effects of novel histamine H2 receptor agonists[J]. J Pharmacol Exp Ther,2021,379(3):223-234. doi: 10.1124/jpet.121.000822
[16]	He G,Hu J,Ma X,et al. Sympathetic histamine exerts different pre- and post-synaptic functions according to the frequencies of nerve stimulation in guinea pig vas deferens[J]. J Neurochem,2008,106(4):1710-9. doi: 10.1111/j.1471-4159.2008.05532.x
[17]	He G,Hu J,Li T,et al. Arrhythmogenic effect of sympathetic histamine in mouse hearts subjected to acute ischemia[J]. Mol Med,2012,18(1):1-9.
[18]	He G H,Cai W K,Meng J R,et al. Relation of polymorphism of the histidine decarboxylase gene to chronic heart failure in Han Chinese[J]. Am J Cardiol,2015,115(11):P1555-1562. doi: 10.1016/j.amjcard.2015.02.062
[19]	Meng R,Chen L R,Zhang M L,et al. Effectiveness and safety of histamine H2 receptor antagonists: An umbrella review of meta-analyses[J]. J Clin Pharmacol,2023,63(1):7-20. doi: 10.1002/jcph.2147
[20]	Zhang J,Cai W K,Zhang Z,et al. Cardioprotective effect of histamine H2 antagonists in congestive heart failure: A systematic review and meta-analysis[J]. Medicine (Baltimore),2018,97(15):e0409.
[21]	Huang Y H,Cai W K,Yin S J,et al. Histamine H2 receptor antagonist exposure was related to decreased all-cause mortality in critical ill patients with heart failure: A cohort study[J]. Eur J PrevCardiol,2022,29(14):1854-1865.
[22]	Sato T,Aikawa T. The role of histamine H2 receptor antagonist in heart failure: A potential game-changer?[J]. Eur J PrevCardiol,2022,29(14):1852-1853.
[23]	Liu Y,Wang Z,Li J,et al. Inhibition of 5-hydroxytryptamine receptor 2B reduced vascular restenosis and mitigated the β-arrestin2-mammalian target of rapamycin/p70S6K pathway[J]. J Am Heart Assoc,2018,7(3):e006810. doi: 10.1161/JAHA.117.006810
[24]	Cidlowski J A,Cruz-Topete D. Glucocorticoid inhibition of estrogen regulation of the serotonin receptor 2B in cardiomyocytes exacerbates cell death in hypoxia/reoxygenation injury[J]. J Am Heart Assoc,2021,10(17):e015868. doi: 10.1161/JAHA.120.015868
[25]	郝德雄,陈明,王玉兵. 5羟色胺2B受体阻滞剂对压力超负荷大鼠心功能的影响[J]. 中华高血压杂志,2016,24(9):863-868.
[26]	Janssen W,Schymura Y,Novoyatleva T,et al. 5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failure[J]. Biomed Res Int,2015,2015:438403.
[27]	Marzak H,Ayme-Dietrich E,Lawson R,et al. Old spontaneously hypertensive rats gather together typical features of human chronic left-ventricular dysfunction with preserved ejection fraction[J]. J Hypertens,2014,32(6):1307-16. doi: 10.1097/HJH.0000000000000159
[28]	Xia H,Zahra A,Jia M,et al. Na⁺/H⁺ exchanger 1,a potential therapeutic drug target for cardiac hypertrophy and heart failure[J]. Pharmaceuticals (Basel),2022,15(7):875. doi: 10.3390/ph15070875
[29]	Sjøgaard-Frich L M,Prestel A,Pedersen E S,et al. Dynamic Na⁺/H⁺ exchanger 1 (NHE1) - calmodulin complexes of varying stoichiometry and structure regulate Ca²⁺-dependent NHE1 activation[J]. Elife,2021,10:e60889. doi: 10.7554/eLife.60889
[30]	Escudero D S,Pérez N G,Díaz R G. Myocardial impact of NHE1 regulation by sildenafil[J]. Front Cardiovasc Med,2021,8:617519. doi: 10.3389/fcvm.2021.617519
[31]	Suleiman M,Abdulrahman N,Yalcin H,et al. The role of CD44,hyaluronan and NHE1 in cardiac remodeling[J]. Life Sci,2018,209:197-201. doi: 10.1016/j.lfs.2018.08.009
[32]	Mohamed I A,Mraiche F. Targeting osteopontin,the silent partner of Na⁺/H⁺ exchanger isoform 1 in cardiac remodeling[J]. J Cell Physiol,2015,230(9):2006-2018. doi: 10.1002/jcp.24958
[33]	Previtali S C,Gidaro T,Díaz-Manera J,et al. Rimeporide as a ﬁrst- in-class NHE-1 inhibitor: Results of a phase Ib trial in young patients with duchenne muscular dystrophy[J]. Pharmacol Res,2020,159:104999. doi: 10.1016/j.phrs.2020.104999
[34]	Chen J,Chen S,Zhang B,et al. SIRT3 as a potential therapeutic target for heart failure[J]. Pharmacol Res,2021,165:105432. doi: 10.1016/j.phrs.2021.105432
[35]	He X,Zeng H,Chen J X. Emerging role of SIRT3 in endothelial metabolism,angiogenesis,and cardiovascular disease[J]. J Cell Physiol,2019,234(3):2252-2265. doi: 10.1002/jcp.27200
[36]	Chen W J,Cheng Y,Li W,et al. Quercetin attenuates cardiac hypertrophy by inhibiting mitochondrial dysfunction through SIRT3/PARP-1 pathway[J]. Front Pharmacol,2021,12:739615. doi: 10.3389/fphar.2021.739615
[37]	Liu J,Tang M,Li T,et al. Honokiol ameliorates post-myocardial infarction heart failure through Ucp3-mediated reactive oxygen species inhibition[J]. Front Pharmacol,2022,13:811682. doi: 10.3389/fphar.2022.811682
[38]	Pillai V B,Samant S,Sundaresan N R,et al. Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial SIRT3[J]. Nat Commun,2015,6:6656. doi: 10.1038/ncomms7656
[39]	马斌,雷贺吉,韩淑伟. 血清肿瘤坏死因子-α、白细胞介素-1β及白细胞介素-6与慢性心力衰竭病人心功能的相关性分析[J]. 中西医结合心脑血管病杂志,2019,17(16):2490-2492. doi: 10.12102/j.issn.1672-1349.2019.16.025
[40]	Hanna A,Frangogiannis N G. Inflammatory cytokines and chemokines as therapeutic targets in heart failure[J]. Cardiovasc Drugs Ther,2020,34(6):849-863. doi: 10.1007/s10557-020-07071-0
[41]	NemecSvete A,Verk B,Čebulj-Kadunc N,et al. Inflammation and its association with oxidative stress in dogs with heart failure[J]. BMC Vet Res,2021,17(1):176. doi: 10.1186/s12917-021-02878-x
[42]	Kotyla P J. Bimodal function of Anti-TNF treatment: shall we be concerned about Anti-TNF treatment in patients with rheumatoid arthritis and heart failure?[J]. Int J Mol Sci,2018,19(6):1739. doi: 10.3390/ijms19061739
[43]	Dinarello C A. The IL-1 family of cytokines and receptors in rheumatic diseases[J]. Nat Rev Rheumatol,2019,15(10):612-632. doi: 10.1038/s41584-019-0277-8
[44]	Abbate A,Toldo S,Marchetti C,et al. Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease[J]. Circ Res,2020,126(9):1260-1280. doi: 10.1161/CIRCRESAHA.120.315937
[45]	Everett B M,Cornel J H,Lainscak M,et al. Anti-Inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure[J]. Circulation,2019,139(10):1289-1299. doi: 10.1161/CIRCULATIONAHA.118.038010
[46]	Szekely Y,Arbel Y. A review of interleukin-1 in heart disease: Where do we stand today?[J]. Cardiol Ther,2018,7(1):25-44.
[47]	Ye Y,Yang X,Long B,et al. Association between a CCL17 genetic variant and risk of coronary artery disease in a Chinese Han population[J]. Circ J,2017,82(1):224-231.
[48]	Zhang Y,Ye Y,Tang X,et al. CCL17 acts as a novel therapeutic target in pathological cardiac hypertrophy and heart failure[J]. J Exp Med,2022,219(8):e20200418. doi: 10.1084/jem.20200418
[49]	Feng G,Bajpai G,Ma P,et al. CCL17 aggravates myocardial injury by suppressing recruitment of regulatory T cells[J]. Circulation,2022,145(10):765-782. doi: 10.1161/CIRCULATIONAHA.121.055888
[50]	Feng G,Zhu C,Lin C Y,et al. CCL17 protects against viral myocarditis by suppressing the recruitment of regulatory T cells[J]. J Am Heart Assoc,2023,12(4):e028442. doi: 10.1161/JAHA.122.028442

Relative Articles(20)

Relative Articles

[1]	Danhong DONG, Weiwen WANG, Dexia LI, Jun YANG, Na LI, Hang MA, Lin LI. Current Status of Drug Treatment for Chronic Heart Failure Patients With Reduced Ejection Fraction in Yunnan： a Single-center Survey. Journal of Kunming Medical University, 2023, 44(8): 77-84. doi: 10.12259/j.issn.2095-610X.S20230822
[2]	Yan QIU, Yinli WANG, Mengmeng YANG, Liangmin GUO, Longhui YUAN. Association between MPV，PDW，PCT and Cardiac Function in Patients with Pulmonary Hypertension. Journal of Kunming Medical University, 2023, 44(12): 121-126. doi: 10.12259/j.issn.2095-610X.S20231219
[3]	Qin XIE, Chunyang ZHAO, Baosu ZHANG, Hongbo ZHAO. Potential Mechanism of Thioridazine in Anti-cervical Cancer. Journal of Kunming Medical University, 2022, 43(3): 13-20. doi: 10.12259/j.issn.2095-610X.S20220317
[4]	Song MEI, Wen JIANG, Xiang-feng BAI, Wen-jie WANG, Dan HUANG, Wei CAO. Efficacy Analysis of Levosimendan in the Treatment of Heart Failure Caused by Severe Coronary Heart Disease. Journal of Kunming Medical University, 2021, 42(1): 72-75. doi: 10.12259/j.issn.2095-610X.S20210121
[5]	Wei-jie SU, Mei-sha ZHANG, Jia-ning LI, Ying LIU, Ding-jie XU, Hong CHANG. Establishment of Rat Myoblast Atrophy Model Induced by Ang Ⅱ. Journal of Kunming Medical University, 2021, 42(10): 8-13. doi: 10.12259/j.issn.2095-610X.S20211026
[6]	Li Jie , Zhang Shi Ming , Yang Shu Lian . . Journal of Kunming Medical University, 2020, 41(01): 31-36.
[7]	Zhang Ti Ling , Zhang Wei Hua , Luo Qing 祎, Xia Hong Ying , Lu Yi Bing . . Journal of Kunming Medical University, 2020, 41(03): 91-95.
[8]	Jian-pei SU, Wei-meng TIAN, Jun GU, Mi-yu HE. Association between C-reactive Protein/Albumin Ratio and Long-term Prognosis in Elderly Patients with Heart Failure. Journal of Kunming Medical University, 2020, 41(12): 128-132. doi: 10.12259/j.issn.2095-610X.S20201236
[9]	Song Fei , Xiang Ying Ying , Mao Zhi Jian , Zhang Xiao Wen . Comparative Study on Releasing Characteristics of Paclitaxel Chitosan Membranes by Two Different Preparative Methods. Journal of Kunming Medical University, 2017, 38(01): 1-7.
[10]	Ye Xue Qun , Nie Lei . . Journal of Kunming Medical University, 2017, 38(02): 95-98.
[11]	Luo Yong Li . Clinical Assessment on the Safety of Cardiac Rehabilitation for the Elderly Patients with Chronic Heart Failure. Journal of Kunming Medical University,
[12]	Li Yan Ping . The Clinical Characteristics of Patients with Chronic Heart Failure with Preserved Ejection Fraction. Journal of Kunming Medical University,
[13]	Yuan Hua Yuan . . Journal of Kunming Medical University,
[14]	Zhang Ji Lei . . Journal of Kunming Medical University,
[15]	Chen Qiu . . Journal of Kunming Medical University,
[16]	Dai Hai Long . . Journal of Kunming Medical University,
[17]	Ding Cheng Yan . . Journal of Kunming Medical University,
[18]	Chang Song Jie . . Journal of Kunming Medical University,
[19]	Huang Yong Kun . Determination and Analysis of Oligosaccharides in Valeriana Jatamansii Jones and 5 Drugs for Gastrointestinal Diseases. Journal of Kunming Medical University,
[20]	. Clinical Analysis of 59 Old Chronic Heart Failure Patients Complicated with Hyponatremia. Journal of Kunming Medical University,